Chinook Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Chinook Therapeutics has a total shareholder equity of $357.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $488.8M and $131.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$297.17m |
| Equity | US$357.04m |
| Total liabilities | US$131.77m |
| Total assets | US$488.81m |
Recent financial health updates
Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?
May 28
Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth
Feb 14Recent updates
Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?
May 28Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth
Feb 14Chinook Therapeutics: Multiple Shots On Goal For IgAN
Aug 31Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%
Aug 12Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line
Aug 08Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease
Jul 05Financial Position Analysis
Short Term Liabilities: KDNY's short term assets ($305.4M) exceed its short term liabilities ($52.5M).
Long Term Liabilities: KDNY's short term assets ($305.4M) exceed its long term liabilities ($79.3M).
Debt to Equity History and Analysis
Debt Level: KDNY is debt free.
Reducing Debt: KDNY had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KDNY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KDNY has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 48.4% each year.